BioMarin Pharmaceutical (BMRN) : Zacks Investment Research ranks BioMarin Pharmaceutical (BMRN) as 3, which is a Hold recommendation. 12 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 2 other analysts are mildly bullish on the stock and favor a Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 1.27, which indicates as a Strong Buy.
BioMarin Pharmaceutical (BMRN) : The highest level BioMarin Pharmaceutical (BMRN) is projected to reach is $150 for the short term and the lowest estimate is at $99. The consolidated price target from 15 rating analysts who initiate coverage on the stock is $120.07 and the possibility the share price can swing is $11.31.
For the current week, the company shares have a recommendation consensus of Buy. BioMarin Pharmaceutical (NASDAQ:BMRN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $91.93 and $90.66 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $92.81. The buying momentum continued till the end and the stock did not give up its gains. It closed at $92.01, notching a gain of 0.61% for the day. The total traded volume was 1,342,818 . The stock had closed at $91.45 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Spiegelman Daniel K, officer (EVP, Chief Financial Officer) of Biomarin Pharmaceutical Inc, had unloaded 4,000 shares at an average price of $99.33 in a transaction dated on August 1, 2016. The total value of the transaction was worth $397,320.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).